One World Cannabis Files 6th Provisional Patent Application With USPTO
PETACH TIKVA, Israel, March 24, 2015 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company"), had their sixth provisional application filled with the USPTO.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
The latest provisional application relates to novel compositions and methods for the administration of pharmaceutical formulations. More specifically, the current invention pertains to an emulsion comprised of enriched concentrations of Tetrahydrocannabinol ("THC"), Cannabidiol ("CBD") or derivatives thereof that may be useful as a novel delivery method for the treatment of various medical conditions.
"This provisional patent application protects key intellectual property relating to unique formulations and specific delivery systems for cannabinoid-based therapies," said One World Cannabis CEO Mr. Ziv Turner. "We plan to continue to file additional patent applications covering our ideas and novel solutions to ultimately pave the way for our breakthrough technologies and drive long-term shareholder value."
About One World Cannabis Ltd.
One World Cannabis Ltd. ("the Company") is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact:
Ziv Turner, CEO
One World Cannabis Ltd. (OWC)
Tel: +972(0)54-5500450
Email: [email protected]
SOURCE OWC Pharmaceutical Research Corp.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article